Garrido A, Brunet S, Calabuig M, et al. Final results of the CETLAM LAM-203 trial fort he treatment of primary AML up tot the age of 70. EHA 2017, abstract S790.
Subcutaan daratumumab bij RRMM non-inferieur aan intraveneuze toediening
mrt 2020 | MM
okt 2020
apr 2020 | Transplantatie
apr 2020
jan 2020 | Leukemie